IGNITE: Safety and Feasibility of MR-HIFU Ablation of Pediatric Solid Tumors
- Aerang Kim, MD, PhD
- Pavel Yarmolenko, PhD
- Haydar Celik, PhD
- Peter Kim, MD, PhD
Cure rate for pediatric cancer has dramatically improved over the past several decades. However, this improvement came at a cost of substantial acute toxicities and late effects of current multi-modal therapy. In addition, prognosis remains poor for many pediatric cancers such as those with solid tumors that present with overt metastatic disease. Thus, a clear need exists for less traumatic and more efficacious therapeutic approaches for pediatric malignancies.
At Children’s National, we currently have the first pediatric solid tumor clinical trial open for enrollment evaluating the safety and feasibility of magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) for the ablation of refractory or relapsed solid tumors. Children and young adults less than 30 years old with histologically confirmed relapsed or refractory solid tumor may be eligible to enroll. Tumor target lesions will be limited to those that are located in bone or soft tissue in close proximity to bone.
We have reviewed several possible candidates for the study and we are continuing to recruit patients. Following completion of this clinical trial, our group plans to continue with the next phase of clinical evaluation of this technology.
Link to our website